Drug Profile
Perifosine - AEterna Zentaris
Alternative Names: AEZS-104; D-21266; KRX-0401; NSC-639966; Perifosin; YHI-1003Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator AEterna Zentaris Inc
- Developer AEterna Zentaris Inc; Yakult Honsha
- Class Antineoplastics; Quaternary ammonium compounds; Radiosensitisers; Small molecules; Trimethyl ammonium compounds
- Mechanism of Action Proto oncogene protein c-akt inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gynaecological cancer
- No development reported Glioma; Neuroblastoma; Solid tumours
- Discontinued Chronic lymphocytic leukaemia; Colorectal cancer; Gastrointestinal stromal tumours; Leukaemia; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Waldenstrom's macroglobulinaemia
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO, Tablet)
- 26 Apr 2022 No development reported - Phase-II for Glioma (Recurrent, Second-line therapy or greater) in USA (PO) (NDR batch 22)
- 11 Nov 2019 Keryx Biopharmaceuticals completed a phase II trial in Glioblastoma (Recurrent, Second-line therapy of greater) in the USA (NCT00590954)